AWH:NSD-Aspira Women's Health Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 3.23

Change

0.00 (0.00)%

Market Cap

USD 0.36B

Volume

0.23M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas. Address: Building III, Austin, TX, United States, 78738

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

N/A

USD64.03B 78.35 54.40
IDXX IDEXX Laboratories Inc

N/A

USD55.46B 77.71 57.14
DXCM DexCom Inc

N/A

USD54.82B 106.14 119.10
ICLR ICON Public Limited Company

N/A

USD22.11B 40.47 40.36
EXAS Exact Sciences Corporation

N/A

USD16.16B N/A N/A
GH Guardant Health Inc

N/A

USD11.09B N/A N/A
NTRA Natera Inc

N/A

USD10.78B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
SYNH Syneos Health Inc

N/A

USD9.23B 39.79 21.13
MEDP Medpace Holdings Inc

N/A

USD6.70B 40.32 30.30

ETFs Containing AWH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.86% 7% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.86% 7% F 7% F
Trailing 12 Months  
Capital Gain -12.23% 45% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.23% 45% F 19% F
Trailing 5 Years  
Capital Gain -97.48% 8% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.48% 8% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -1.56% 23% F 18% F
Dividend Return 1.57% 50% F 44% F
Total Return 0.01% 25% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 23.46% 89% B+ 70% C-
Risk Adjusted Return 0.06% 25% F 20% F
Market Capitalization 0.36B 45% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.10 68% D+ 51% F
Price/Book Ratio 7.32 33% F 19% F
Price / Cash Flow Ratio -24.57 84% B 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.36% 23% F 20% F
Return on Invested Capital -147.17% 9% F 4% F
Return on Assets -44.10% 8% F 6% F
Debt to Equity Ratio 31.66% 57% F 49% F
Technical Ratios  
Short Ratio 18.94 3% F 2% F
Short Percent 11.54% 10% F 14% F
Beta 3.05 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.